GEN Announces First Patient Dosed in Phase II Clinical Trial of SUL-238 in Parkinson's Disease

Proof-of-concept SHEPHERD study will assess SUL-238's effects on mitochondrial function in patients with Parkinson's disease. ANKARA, TR / ACCESS Newswire / June 8, 2026 / GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical …